Ignite Creation Date:
2025-12-24 @ 2:56 PM
Ignite Modification Date:
2025-12-26 @ 5:13 PM
Study NCT ID:
NCT03520959
Status:
TERMINATED
Last Update Posted:
2020-04-16
First Post:
2018-03-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2020-04-01', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D013584', 'term': 'Sarcoma, Synovial'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D012509', 'term': 'Sarcoma'}], 'ancestors': [{'id': 'D009372', 'term': 'Neoplasms, Connective Tissue'}, {'id': 'D018204', 'term': 'Neoplasms, Connective and Soft Tissue'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrialsDisclosure@merck.com', 'phone': '1-800-672-6372', 'title': 'Senior Vice President, Global Clinical Development', 'organization': 'Merck Sharp & Dohme Corp.'}, 'certainAgreement': {'restrictionType': 'LTE60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'Study was stopped early due to Sponsor decision.'}}, 'adverseEventsModule': {'timeFrame': 'Up to approximately 2 months', 'description': '0 participants are reported due to the risk of identification of a person.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo', 'description': 'CMB305 placebo control', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 0, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 0, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Progression-Free Survival (PFS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'CMB305 placebo control'}, {'id': 'OG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]'}], 'timeFrame': 'From randomization to investigator-determined date of disease progression or death, assessed up to 24 months.', 'description': 'PFS is defined as the time from randomization to the investigator-determined date of disease progression or death, whichever comes first, using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).', 'reportingStatus': 'POSTED', 'populationDescription': 'No data were collected or analyzed for this outcome measure due to early termination of the study.'}, {'type': 'PRIMARY', 'title': 'Overall Survival (OS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'CMB305 placebo control'}, {'id': 'OG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]'}], 'timeFrame': 'From randomization to date of death, assessed up to 66 months.', 'description': 'OS is defined as the time from randomization to the date of death.', 'reportingStatus': 'POSTED', 'populationDescription': 'No data were collected or analyzed for this outcome measure due to early termination of the study.'}, {'type': 'SECONDARY', 'title': 'Time to Next Treatment (TTNT)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'CMB305 placebo control'}, {'id': 'OG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]'}], 'timeFrame': 'From last dose of CMB305 to initiation of new therapy, assessed up to 24 months.', 'description': 'TTNT is defined as the time from randomization to the start of post-study treatment subsequent intervention: \\[TTNT = start date of subsequent intervention - randomization date + 1\\]. Subsequent intervention includes anticancer therapy, cancer-related surgery and local regional therapy. Participants who do not start any post-study treatment intervention will be censored at their last known date of being alive.', 'reportingStatus': 'POSTED', 'populationDescription': 'No data were collected or analyzed for this outcome measure due to early termination of the study.'}, {'type': 'SECONDARY', 'title': 'Distant Metastasis Free Survival (DMFS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'CMB305 placebo control'}, {'id': 'OG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]'}], 'timeFrame': 'From randomization to investigator-determined date of disease progression or death, assessed up to 24 months.', 'description': 'DMFS is defined as the time from randomization to evidence of a new distant metastasis not documented at time of randomization: \\[DMFS = a new distant metastasis documented date - randomization date + 1\\]. Participants who do not have any new distant metastasis will be censored at their last tumor assessment.', 'reportingStatus': 'POSTED', 'populationDescription': 'No data were collected or analyzed for this outcome measure due to early termination of the study.'}, {'type': 'SECONDARY', 'title': 'Overall Response Rate (ORR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'CMB305 placebo control'}, {'id': 'OG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]'}], 'timeFrame': 'From randomization to investigator-determined date of disease progression, assessed up to 24 months.', 'description': "ORR defined by RECIST v1.1 will be summarized by the number and percent of subjects who achieve a complete response (CR) or partial response (PR) based on the investigator's assessment. ORR will be compared between treatment arms using a logistic regression.", 'reportingStatus': 'POSTED', 'populationDescription': 'No data were collected or analyzed for this outcome measure due to early termination of the study.'}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'CMB305 placebo control'}, {'id': 'OG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From randomization to investigator-determined date of disease progression or death, assessed up to approximately 2 months.', 'description': 'Safety will be assessed primarily based on reported adverse events (AEs), Medical Events of Interest (MEOIs), laboratory values, and concomitant medications reported from initiation of treatment with CMB305 or placebo.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants taking any amount of study drug.'}, {'type': 'SECONDARY', 'title': 'Quality of Life (QoL): EuroQol 5-Dimension 5 Level (EQ-5D-5L) and EuroQol 5-Dimension Youth (EQ-5D-Y) Questionnaires', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'CMB305 placebo control'}, {'id': 'OG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]'}], 'timeFrame': 'From Day 1 up to 12 months', 'description': 'QoL evaluated using the EQ-5D-5L for participants ≥18 years of age or using the EQ-5D-Y for participants 12 to \\<18 years of age. EQ-5D-5L descriptive system is comprised of 5 dimensions-mobility, self-care, usual activities, pain/discomfort \\& anxiety/depression. Each dimension has 5 levels: not at all (level 1), mild (level 2), moderate (level 3), severe (level 4), extreme/leading to incapacity (level 5), with highest level corresponding to worst outcome. Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value using the EQ-5D-5L crosswalk index value calculator as recommended by EuroQol group. In the EQ-VAS, participants recorded their health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).', 'reportingStatus': 'POSTED', 'populationDescription': 'No data were collected or analyzed for this outcome measure due to early termination of the study.'}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Discontinued Study Treatment Due to an AE', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'CMB305 placebo control'}, {'id': 'OG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Up to approximately 2 months', 'description': 'The number of all participants who discontinued study treatment due to an AE is presented.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants taking any amount of study drug.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo', 'description': 'CMB305 placebo control'}, {'id': 'FG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Study terminated by Sponsor', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo', 'description': 'CMB305 placebo control'}, {'id': 'BG001', 'title': 'CMB305', 'description': 'CMB305: Sequentially administered LV305 \\[lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene\\] and G305 \\[NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}\\]'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years'}, {'title': 'Between 18 and 65 years'}, {'title': '>=65 years'}]}]}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female'}, {'title': 'Male'}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino'}, {'title': 'Not Hispanic or Latino'}, {'title': 'Unknown or Not Reported'}]}]}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native'}, {'title': 'Asian'}, {'title': 'Native Hawaiian or Other Pacific Islander'}, {'title': 'Black or African American'}, {'title': 'White'}, {'title': 'More than one race'}, {'title': 'Unknown or Not Reported'}]}]}], 'populationDescription': '0 participants are reported due to the risk of identification of a person.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-09-19', 'size': 1198513, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2020-03-19T13:03', 'hasProtocol': True}, {'date': '2018-05-25', 'size': 1026514, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2020-03-19T13:03', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1}}, 'statusModule': {'whyStopped': "Study was terminated due to sponsor's decision.", 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2018-09-18', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-04', 'completionDateStruct': {'date': '2018-11-20', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-04-03', 'studyFirstSubmitDate': '2018-03-30', 'resultsFirstSubmitDate': '2020-02-26', 'studyFirstSubmitQcDate': '2018-04-27', 'lastUpdatePostDateStruct': {'date': '2020-04-16', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-04-03', 'studyFirstPostDateStruct': {'date': '2018-05-11', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2020-04-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-11-20', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression-Free Survival (PFS)', 'timeFrame': 'From randomization to investigator-determined date of disease progression or death, assessed up to 24 months.', 'description': 'PFS is defined as the time from randomization to the investigator-determined date of disease progression or death, whichever comes first, using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'From randomization to date of death, assessed up to 66 months.', 'description': 'OS is defined as the time from randomization to the date of death.'}], 'secondaryOutcomes': [{'measure': 'Time to Next Treatment (TTNT)', 'timeFrame': 'From last dose of CMB305 to initiation of new therapy, assessed up to 24 months.', 'description': 'TTNT is defined as the time from randomization to the start of post-study treatment subsequent intervention: \\[TTNT = start date of subsequent intervention - randomization date + 1\\]. Subsequent intervention includes anticancer therapy, cancer-related surgery and local regional therapy. Participants who do not start any post-study treatment intervention will be censored at their last known date of being alive.'}, {'measure': 'Distant Metastasis Free Survival (DMFS)', 'timeFrame': 'From randomization to investigator-determined date of disease progression or death, assessed up to 24 months.', 'description': 'DMFS is defined as the time from randomization to evidence of a new distant metastasis not documented at time of randomization: \\[DMFS = a new distant metastasis documented date - randomization date + 1\\]. Participants who do not have any new distant metastasis will be censored at their last tumor assessment.'}, {'measure': 'Overall Response Rate (ORR)', 'timeFrame': 'From randomization to investigator-determined date of disease progression, assessed up to 24 months.', 'description': "ORR defined by RECIST v1.1 will be summarized by the number and percent of subjects who achieve a complete response (CR) or partial response (PR) based on the investigator's assessment. ORR will be compared between treatment arms using a logistic regression."}, {'measure': 'Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE)', 'timeFrame': 'From randomization to investigator-determined date of disease progression or death, assessed up to approximately 2 months.', 'description': 'Safety will be assessed primarily based on reported adverse events (AEs), Medical Events of Interest (MEOIs), laboratory values, and concomitant medications reported from initiation of treatment with CMB305 or placebo.'}, {'measure': 'Quality of Life (QoL): EuroQol 5-Dimension 5 Level (EQ-5D-5L) and EuroQol 5-Dimension Youth (EQ-5D-Y) Questionnaires', 'timeFrame': 'From Day 1 up to 12 months', 'description': 'QoL evaluated using the EQ-5D-5L for participants ≥18 years of age or using the EQ-5D-Y for participants 12 to \\<18 years of age. EQ-5D-5L descriptive system is comprised of 5 dimensions-mobility, self-care, usual activities, pain/discomfort \\& anxiety/depression. Each dimension has 5 levels: not at all (level 1), mild (level 2), moderate (level 3), severe (level 4), extreme/leading to incapacity (level 5), with highest level corresponding to worst outcome. Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value using the EQ-5D-5L crosswalk index value calculator as recommended by EuroQol group. In the EQ-VAS, participants recorded their health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).'}, {'measure': 'Number of Participants Who Discontinued Study Treatment Due to an AE', 'timeFrame': 'Up to approximately 2 months', 'description': 'The number of all participants who discontinued study treatment due to an AE is presented.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Synovate Study', 'NY-ESO-1', 'cancer vaccine', 'Sarcoma', 'soft tissue sarcoma', 'immunotherapy'], 'conditions': ['Synovial Sarcoma', 'Cancer', 'Soft Tissue Sarcoma', 'Sarcoma', 'Metastatic Sarcoma']}, 'descriptionModule': {'briefSummary': "To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.", 'detailedDescription': 'The Synovate Study is a global, randomized, double-blind, placebo-controlled, phase 3 study in patients with unresectable, locally-advanced or metastatic New York esophageal squamous cell carcinoma 1 (NY-ESO-1) positive synovial sarcoma following first-line systemic anti-cancer therapy.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '12 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Selected Inclusion Criteria:\n\n* Histological diagnosis of synovial sarcoma\n* Immunohistochemistry (IHC) results from tumor biopsy for New York esophageal squamous cell carcinoma 1 (NY-ESO-1) are positive\n* Participants have received at least 4 but no more than 8 cycles of first-line anthracycline or ifosfamide-containing systemic anti-cancer therapy regimen\n* Must have documentation of no evidence of disease progression of the tumor during or after completion of first line systemic anti-cancer therapy\n* ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1\n* Age \\>/= 12 years\n* Life expectancy of at least 6 months\n\nSelected Exclusion Criteria:\n\n* Have received last dose of first-line systemic anti-cancer therapy or date of most recent local regional therapy \\>28 days prior to day 1\n* Have received prior anti-NY-ESO-1 therapy\n* Have received first-line systemic anti-cancer therapy with an agent other than anthracycline or ifosfamide\n* Have received treatment with systemic immunomodulatory agents within 28 days prior to administration of the first dose of CMB305, or 5 half-lives of the drug, whichever occurs sooner.\n* Have significant immunosuppression from concurrent, recent, or anticipated need for chronic treatment with systemic immunosuppressive dose of corticosteroids or immunosuppressive medications.\n* Have psychiatric or other medical illness, or any other condition that in the opinion of the investigator prevents compliance with the study procedures or ability to provide valid informed consent.\n* Have history of uncontrolled autoimmune disease.\n* Have a significant electrocardiogram finding or cardiovascular disease\n* have inadequate organ function per protocol\n* History of other cancer within 3 years\n* Evidence of active tuberculosis or recent clinically-significant infection requiring systemic therapy.\n* Evidence of active Hepatitis B, Hepatitis C, or Human Immunodeficiency virus (HIV) infection\n* Have a history of brain metastasis\n* Have received cancer therapies including chemotherapy, radiation, biologic, or kinase inhibitors, granulocyte-colony stimulating factor (G-CSF), or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 3 weeks prior ot the first scheduled dose of CMB305\n* Female of child bearing potential who is pregnant, is planning to become pregnant, or is breast feeding; or male who is sexually active with a female of child bearing potential who is planning to become pregnant.'}, 'identificationModule': {'nctId': 'NCT03520959', 'briefTitle': 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'}, 'officialTitle': 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Participants Following First Line Systemic Anti-cancer Therapy (V943-003, IMDZ-04-1702)', 'orgStudyIdInfo': {'id': 'IMDZ-04-1702'}, 'secondaryIdInfos': [{'id': 'V943A-003', 'type': 'OTHER', 'domain': 'Merck Unique ID'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'A sequential regimen of LV305-matching placebo and G305-matching placebo.', 'interventionNames': ['Other: LV305-matching placebo', 'Other: G305-matching placebo']}, {'type': 'EXPERIMENTAL', 'label': 'CMB305', 'description': 'A sequential regimen of LV305 and G305.', 'interventionNames': ['Biological: LV305', 'Biological: G305']}], 'interventions': [{'name': 'LV305', 'type': 'BIOLOGICAL', 'description': 'Administered via subcutaneous (SC) injection.', 'armGroupLabels': ['CMB305']}, {'name': 'G305', 'type': 'BIOLOGICAL', 'description': 'Administered via intramuscular (IM) injection.', 'armGroupLabels': ['CMB305']}, {'name': 'LV305-matching placebo', 'type': 'OTHER', 'description': 'Administered via SC injection.', 'armGroupLabels': ['Placebo']}, {'name': 'G305-matching placebo', 'type': 'OTHER', 'description': 'Administered via IM injection.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85259', 'city': 'Scottsdale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Mayo Clinic- Scottsdale', 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'zip': '85724', 'city': 'Tucson', 'state': 'Arizona', 'country': 'United States', 'facility': 'University of Arizona Cancer Center', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '90033', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'USC Norris Comprehensive Cancer Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '94305', 'city': 'Palo Alto', 'state': 'California', 'country': 'United States', 'facility': 'Stanford University', 'geoPoint': {'lat': 37.44188, 'lon': -122.14302}}, {'zip': '90403', 'city': 'Santa Monica', 'state': 'California', 'country': 'United States', 'facility': 'Sarcoma Oncology Center', 'geoPoint': {'lat': 34.01949, 'lon': -118.49138}}, {'zip': '80309', 'city': 'Boulder', 'state': 'Colorado', 'country': 'United States', 'facility': 'University of Colorado Cancer Center', 'geoPoint': {'lat': 40.01499, 'lon': -105.27055}}, {'zip': '06520', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Yale University School of Medicine- Cancer Center', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '33146', 'city': 'Coral Gables', 'state': 'Florida', 'country': 'United States', 'facility': 'University of Miami', 'geoPoint': {'lat': 25.72149, 'lon': -80.26838}}, {'zip': '32224', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'Mayo Clinic- Jacksonville', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '33612', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Moffitt Cancer Center at USF', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Northwestern', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Dana Farber Cancer Institute/Mass General Hospital', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Washington University in St. Louis', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '68114', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Nebraska Methodist Hospital', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '08837', 'city': 'Edison', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Hackensack University Medical Center', 'geoPoint': {'lat': 40.51872, 'lon': -74.4121}}, {'zip': '11105', 'city': 'Astoria', 'state': 'New York', 'country': 'United States', 'facility': "Cohen Children's Medical Center (Northwell)", 'geoPoint': {'lat': 40.77205, 'lon': -73.93014}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '27708', 'city': 'Durham', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Duke University', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '45229', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': "Cincinnati Children's Hospital", 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Ohio State University', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '97239', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Health and Science University', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '19111', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Fox Chase Cancer Center', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '15224', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'University of Pittsburgh Medical Center', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '37232', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Vanderbilt University Medical Center', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'MD Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '98109', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'city': 'Edmonton', 'country': 'Canada', 'facility': 'University of Alberta Hospital- Cross Cancer Institute', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'city': 'Montreal East', 'country': 'Canada', 'facility': 'McGill University', 'geoPoint': {'lat': 45.63202, 'lon': -73.5075}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}